Summary
After rapid intravenous injection of furosemide 40 mg (Fu), plasma levels were determined in 7 healthy volunteers, 8 patients with liver cirrhosis with ascites and 7 patients with end-stage renal disease (ESRD). The diuretic response was evaluated by measuring the urinary excretion of sodium and potassium and the urine volume. The mean elimination half life (tF1/2+) of Fu averaged 51±7.7 (±SD) min in healthy subjects, 52±7.7 min in cirrhosis and 200±57 min in ESRD. The non-renal clearance (Clnr) in healthy subjects (56±28 ml/min) corresponds to the total plasma clearance in functionally anephric patients (54±18 ml/min). In cirrhosis there was no significant change in the disposition parameters of Fu in comparison to the healthy volunteers, but there was a significant reduction in urine sodium and volume, whereas potassium excretion remained unchanged. Fu “excretion rate — response” curves showed diminished tubular sensitivity to Fu in cirrhosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alexander WA, Levine DF, Branch RA, Hartog M (1977) Urinary sodium/potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 53: 117–121
Andreasen F, Jakobsen P (1974) Determination of furosemide in blood plasma and its binding to proteins in normal plasma from patients with acute renal failure. Acta Pharmacol Toxicol 35: 49–57
Andreasen F, Mikkelsen E (1977) Distribution, elimination and effects of furosemide in normal subjects and in patients with heart failure. Eur J Pharmacol 12: 15–22
Beermann B, Dalen E, Lindström B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78
Benet L (1979) Pharmacokinetics, pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm 7: 1–27
Branch R, Roberts C, Homeida M, Levine D (1977) Determinants of response to furosemide in normal subjects. Br J Clin Pharmacol 4: 121–127
Brater C, Chennavasin P, Seiwell R, Beck J (1980) Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 28: 182–186
Chennavasin P, Seiwell R, Brater DC, Liang WM (1979) Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 16: 187–195
Cutler R, Forrey A, Christopher T, Kimpel B (1974) Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15: 588–596
Cutler R, Blair A (1979) Clinical pharmacokinetics of furosemide. Clin Pharmacokinet 4: 279–296
Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1: 126–134
Hoppe-Seyler G (1980) Pharmakokinetik und Pharmakodynamik von Diuretika. Diuretika, edition medizin, Weinheim, pp 103–111
Huang CM, Atkinson A, Levin M, Quintanilla A (1974) Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16: 659–666
Kind H, Schmid E (1969) Über die Harnausscheidung von Furosemid bei Gesunden und Kranken mit Leberzirrhose. Pharmacol Clin 2: 221–226
Kleinfelder H (1963) Experimentelle Untersuchungen und klinische Erfahrungen mit einem neuen Diuretikum. Dtsch Med Wochenschr 88: 1695–1702
Lawrence J, Ansari F, Elliott L, Summer J, Brunton F, Whiting B, Whitesmith R (1978) Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther 23: 558–565
Lindström B, Molander M (1974) Gas chromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector. J Chromatogr 101: 219–221
Lopez-Novoa JM, Rengel MA, Rodicio JL, Hernando L (1977) A micropuncture study of salt and water retention in chronic experimental cirrhosis. Am J Physiol 232: 315–318
Naranja C, Pontigo E, Valdenegro C, Gonzales G, Ruiz I, Busto U (1979) Furosemide-induced adverse reactions in cirrhosis of the liver. Clin Pharmacol Ther 25: 154–160
Odlind B, Beermann B (1980) Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 27: 784–790
Prandotta J, Pruitt AW (1975) Furosemide binding to human albumin in plasma of nephrotic children. Clin Pharmacol Ther 17: 159–166
Rane A, Villeneuve J, Stone W, Nies A, Wilkinson G, Branch R (1978) Plasma binding and disposition of furosemide in the nephrotic syndrom and in uremia. Clin Pharmacol Ther 24: 199–207
Rupp W, Heidland A, Neuhaus G (1970) Pharmakokinetik von Furosemid bei normaler und eingeschränkter Nierenfunktion. Freiburger Tagung über Nephrologie 1970. Thieme, Stuttgart, p 24
Tilstone W, Fine A (1978) Furosemide kinetics in renal failure. Clin Pharmacol Ther 23: 644–650
Author information
Authors and Affiliations
Additional information
Preliminary results were reported at the 86th Annual Meeting of the Deutsche Gesellschaft für Innere Medizin
Rights and permissions
About this article
Cite this article
Keller, E., Hoppe-Seyler, G., Mumm, R. et al. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20, 27–33 (1981). https://doi.org/10.1007/BF00554663
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00554663